BINEX Co., Ltd. (053030.KQ)
KRW 15870.0
(2.39%)
KRW 15870.0
(2.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 75.68 Billion KRW | -28.68% |
| 2022 | 106.12 Billion KRW | 16.22% |
| 2021 | 91.31 Billion KRW | -4.94% |
| 2020 | 96.05 Billion KRW | 132.0% |
| 2019 | 41.4 Billion KRW | 8.51% |
| 2018 | 38.15 Billion KRW | 5.84% |
| 2017 | 36.04 Billion KRW | 2.04% |
| 2016 | 35.32 Billion KRW | 9.74% |
| 2015 | 32.18 Billion KRW | 0.0% |
| 2013 | 24.82 Billion KRW | -52.18% |
| 2012 | 51.9 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 92.76 Billion KRW | 18.68% |
| 2024 Q1 | 78.16 Billion KRW | 3.28% |
| 2023 Q2 | 96.04 Billion KRW | -15.08% |
| 2023 Q3 | 94.81 Billion KRW | -1.28% |
| 2023 FY | 75.68 Billion KRW | -28.68% |
| 2023 Q4 | 75.68 Billion KRW | -20.18% |
| 2023 Q1 | 113.1 Billion KRW | 6.57% |
| 2022 Q1 | 93.73 Billion KRW | 2.65% |
| 2022 Q4 | 106.12 Billion KRW | 8.27% |
| 2022 Q3 | 98.02 Billion KRW | 3.13% |
| 2022 Q2 | 95.04 Billion KRW | 1.39% |
| 2022 FY | 106.12 Billion KRW | 16.22% |
| 2021 FY | 91.31 Billion KRW | -4.94% |
| 2021 Q3 | 75.44 Billion KRW | -1.41% |
| 2021 Q4 | 91.31 Billion KRW | 21.03% |
| 2021 Q1 | 89.35 Billion KRW | -6.97% |
| 2021 Q2 | 76.52 Billion KRW | -14.37% |
| 2020 Q4 | 96.05 Billion KRW | 143.88% |
| 2020 FY | 96.05 Billion KRW | 132.0% |
| 2020 Q3 | 39.38 Billion KRW | 7.92% |
| 2020 Q2 | 36.49 Billion KRW | -15.69% |
| 2020 Q1 | 43.29 Billion KRW | 4.56% |
| 2019 Q2 | 38.76 Billion KRW | 10.25% |
| 2019 FY | 41.4 Billion KRW | 8.51% |
| 2019 Q4 | 41.4 Billion KRW | 3.06% |
| 2019 Q3 | 40.17 Billion KRW | 3.64% |
| 2019 Q1 | 35.15 Billion KRW | -5.74% |
| 2018 FY | 38.15 Billion KRW | 5.84% |
| 2018 Q4 | 37.3 Billion KRW | 8.55% |
| 2018 Q3 | 34.36 Billion KRW | 3.34% |
| 2018 Q2 | 33.25 Billion KRW | -3.93% |
| 2018 Q1 | 34.61 Billion KRW | -3.98% |
| 2017 FY | 36.04 Billion KRW | 2.04% |
| 2017 Q1 | 37.15 Billion KRW | 5.18% |
| 2017 Q2 | 36.62 Billion KRW | -1.42% |
| 2017 Q4 | 36.04 Billion KRW | 0.0% |
| 2017 Q3 | - KRW | -100.0% |
| 2016 Q2 | 33.66 Billion KRW | -3.62% |
| 2016 FY | 35.32 Billion KRW | 9.74% |
| 2016 Q4 | 35.32 Billion KRW | 7.47% |
| 2016 Q3 | 32.87 Billion KRW | -2.36% |
| 2016 Q1 | 34.92 Billion KRW | 9.25% |
| 2015 Q4 | 31.97 Billion KRW | 0.0% |
| 2015 FY | 32.18 Billion KRW | 0.0% |
| 2014 Q3 | 29.88 Billion KRW | -3.63% |
| 2014 Q1 | 25.04 Billion KRW | 0.92% |
| 2014 Q2 | 31.01 Billion KRW | 23.8% |
| 2013 Q2 | 29.31 Billion KRW | -16.44% |
| 2013 FY | 24.82 Billion KRW | -52.18% |
| 2013 Q4 | 24.82 Billion KRW | -19.51% |
| 2013 Q3 | 30.83 Billion KRW | 5.21% |
| 2013 Q1 | 35.07 Billion KRW | -32.42% |
| 2012 Q4 | 51.9 Billion KRW | 31.99% |
| 2012 FY | 51.9 Billion KRW | 0.0% |
| 2012 Q3 | 39.32 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 55.341% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -3925.078% |
| Bioneer Corporation | 80.61 Billion KRW | 6.109% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -278.681% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 44.24% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 22.629% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -2.894% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 92.921% |
| Medy-Tox Inc. | 137.14 Billion KRW | 44.811% |
| Peptron, Inc. | 16.36 Billion KRW | -362.375% |
| Amicogen, Inc. | 248.12 Billion KRW | 69.497% |
| Genexine, Inc. | 79.68 Billion KRW | 5.016% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -158.526% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -83.344% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 30.088% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -3.557% |
| SillaJen, Inc. | 19.4 Billion KRW | -290.115% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 57.739% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -44.194% |
| Genomictree Inc. | 7.81 Billion KRW | -868.81% |
| MedPacto, Inc. | 9.56 Billion KRW | -691.221% |
| D&D Pharmatech | 23.98 Billion KRW | -215.547% |
| EASY BIO,Inc. | 105.86 Billion KRW | 28.51% |
| GI Innovation, Inc. | 9.63 Billion KRW | -685.434% |